Average Weight Loss: In one prominent clinical trial (SURPASS-2), patients taking Tirzepatide saw an average weight loss of around 15-20% of their body weight after 6 months of treatment.This result was significantly higher compared to other treatments for diabetes and weight loss
Neuroinflammation and oxidative stress are key pathological features of PD [8, 9]
For weight management, it's specifically indicated as an adjunct to reduced-calorie diet and increased physical activity in adults with a BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
S., Larkin, L., McCabe, M., & Sadovsky, R
Peptide therapy is highly individualized, and pricing varies depending on: A consultation is required to determine your ideal protocol and provide transparent pricing
Now the other thing that I would say is if you're a clinician